FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4226290879> ?p ?o ?g. }

• W4226290879 endingPage "2312" @default.
• W4226290879 startingPage "2306" @default.
• W4226290879 abstract "Leiomyosarcoma and liposarcoma frequently express PD-L1 but are generally resistant to PD-1/PD-L1 inhibition (immune checkpoint inhibitor). Trabectedin is FDA approved for leiomyosarcoma and liposarcoma. This study aimed to evaluate the safety and efficacy of trabectedin with anti-PD-L1 antibody avelumab in patients with advanced leiomyosarcoma and liposarcoma.A single-arm, open-label, Phase 1/2 study tested avelumab with trabectedin for advanced leiomyosarcoma and liposarcoma. The phase I portion evaluated safety and feasibility of trabectedin (1, 1.2, and 1.5 mg/m2) with avelumab at standard dosing. Primary endpoint of the phase II portion was objective response rate (ORR) by RECIST 1.1. Correlative studies included T-cell receptor sequencing (TCRseq), multiplex IHC, and tumor gene expression.33 patients were evaluable: 24 with leiomyosarcoma (6 uterine and 18 non-uterine) and 11 with liposarcoma. In Phase 1, dose-limiting toxicities (DLT) were observed in 2 of 6 patients at both trabectedin 1.2 and 1.5 mg/m2. The recommended Phase 2 dose (RP2D) was 1.0 mg/m2 trabectedin and 800-mg avelumab. Of 23 patients evaluable at RP2D, 3 (13%) had partial response (PR) and 10 (43%) had stable disease (SD) as best response. Six-month PFS was 52%; median PFS was 8.3 months. Patients with PR had higher Simpson Clonality score on TCRseq from peripheral blood mononuclear cells versus those with SD (0.182 vs. 0.067, P = 0.02) or progressive disease (0.182 vs. 0.064, P = 0.01).Although the trial did not meet the primary objective response rate endpoint, PFS compared favorably with prior studies of trabectedin warranting further investigation." @default.
• W4226290879 created "2022-05-05" @default.
• W4226290879 creator A5004320408 @default.
• W4226290879 creator A5006022670 @default.
• W4226290879 creator A5013176389 @default.
• W4226290879 creator A5015483526 @default.
• W4226290879 creator A5017330947 @default.
• W4226290879 creator A5023928127 @default.
• W4226290879 creator A5026451121 @default.
• W4226290879 creator A5029224737 @default.
• W4226290879 creator A5033280951 @default.
• W4226290879 creator A5034857758 @default.
• W4226290879 creator A5035441899 @default.
• W4226290879 creator A5048969933 @default.
• W4226290879 creator A5058943490 @default.
• W4226290879 creator A5086593114 @default.
• W4226290879 creator A5087296793 @default.
• W4226290879 date "2022-03-01" @default.
• W4226290879 modified "2023-10-17" @default.
• W4226290879 title "A Phase 1/2 Trial Combining Avelumab and Trabectedin for Advanced Liposarcoma and Leiomyosarcoma" @default.
• W4226290879 cites W1955072209 @default.
• W4226290879 cites W1989223689 @default.
• W4226290879 cites W1995830102 @default.
• W4226290879 cites W2069308265 @default.
• W4226290879 cites W2074640340 @default.
• W4226290879 cites W2079728908 @default.
• W4226290879 cites W2096616470 @default.
• W4226290879 cites W2098425296 @default.
• W4226290879 cites W2108750263 @default.
• W4226290879 cites W2117431699 @default.
• W4226290879 cites W2136344041 @default.
• W4226290879 cites W2139184957 @default.
• W4226290879 cites W2164721179 @default.
• W4226290879 cites W2377997829 @default.
• W4226290879 cites W2559588208 @default.
• W4226290879 cites W2581137505 @default.
• W4226290879 cites W2610035536 @default.
• W4226290879 cites W2610371878 @default.
• W4226290879 cites W2653632515 @default.
• W4226290879 cites W2698787169 @default.
• W4226290879 cites W2762797139 @default.
• W4226290879 cites W2783070348 @default.
• W4226290879 cites W2928276758 @default.
• W4226290879 cites W2944423827 @default.
• W4226290879 cites W2946173685 @default.
• W4226290879 cites W2967300456 @default.
• W4226290879 cites W2998268542 @default.
• W4226290879 cites W3014683777 @default.
• W4226290879 cites W3029633823 @default.
• W4226290879 cites W3083776688 @default.
• W4226290879 cites W3088865133 @default.
• W4226290879 cites W3099993684 @default.
• W4226290879 cites W3158020701 @default.
• W4226290879 cites W3196563977 @default.
• W4226290879 cites W4210369711 @default.
• W4226290879 cites W4214925465 @default.
• W4226290879 cites W4225313215 @default.
• W4226290879 cites W4225394054 @default.
• W4226290879 doi "https://doi.org/10.1158/1078-0432.ccr-22-0240" @default.
• W4226290879 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35349638" @default.
• W4226290879 hasPublicationYear "2022" @default.
• W4226290879 type Work @default.
• W4226290879 citedByCount "12" @default.
• W4226290879 countsByYear W42262908792022 @default.
• W4226290879 countsByYear W42262908792023 @default.
• W4226290879 crossrefType "journal-article" @default.
• W4226290879 hasAuthorship W4226290879A5004320408 @default.
• W4226290879 hasAuthorship W4226290879A5006022670 @default.
• W4226290879 hasAuthorship W4226290879A5013176389 @default.
• W4226290879 hasAuthorship W4226290879A5015483526 @default.
• W4226290879 hasAuthorship W4226290879A5017330947 @default.
• W4226290879 hasAuthorship W4226290879A5023928127 @default.
• W4226290879 hasAuthorship W4226290879A5026451121 @default.
• W4226290879 hasAuthorship W4226290879A5029224737 @default.
• W4226290879 hasAuthorship W4226290879A5033280951 @default.
• W4226290879 hasAuthorship W4226290879A5034857758 @default.
• W4226290879 hasAuthorship W4226290879A5035441899 @default.
• W4226290879 hasAuthorship W4226290879A5048969933 @default.
• W4226290879 hasAuthorship W4226290879A5058943490 @default.
• W4226290879 hasAuthorship W4226290879A5086593114 @default.
• W4226290879 hasAuthorship W4226290879A5087296793 @default.
• W4226290879 hasBestOaLocation W42262908791 @default.
• W4226290879 hasConcept C126322002 @default.
• W4226290879 hasConcept C126894567 @default.
• W4226290879 hasConcept C141071460 @default.
• W4226290879 hasConcept C142724271 @default.
• W4226290879 hasConcept C143998085 @default.
• W4226290879 hasConcept C2776694085 @default.
• W4226290879 hasConcept C2777532014 @default.
• W4226290879 hasConcept C2778256501 @default.
• W4226290879 hasConcept C2778629024 @default.
• W4226290879 hasConcept C2778822529 @default.
• W4226290879 hasConcept C2779568860 @default.
• W4226290879 hasConcept C2779984678 @default.
• W4226290879 hasConcept C2780752271 @default.
• W4226290879 hasConcept C71924100 @default.
• W4226290879 hasConceptScore W4226290879C126322002 @default.
• W4226290879 hasConceptScore W4226290879C126894567 @default.

• next